Home › Breast Cancer › NCT06072807
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
Brain [18F]-FES PET/CT in the Diagnosis, Treatment Planning and Response Assessment of Brain Metastases in Patients With Estrogen-Receptor Positive Breast Cancer
Who can join
Ages 18 and older · Women
Full eligibility criteria
Inclusion Criteria: 1. Active diagnosis of ER+ breast cancer (biopsy proven) and new or recurrent brain metastases (biopsy proven or suspected based on MRI appearance) 2. Ability to provide informed consent 3. Discontinuation of ER modulators for at least 8 weeks, and discontinuation of ER down regulators for at least 28 weeks (as per manufacturer guidelines) 4. Age \>=18 years 5. Eastern Cooperative Oncology Group performance score 0-1 6. Life expectancy \>=6 months 7. Planned for radiation treatment for brain metastases Exclusion Criteria: 1. Pregnancy 2. Unable to undergo Standard of Care 3. Allergy to FES.
About the study
The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases. Patients will undergo MRI of the brain and FDG PET/CT brain as part of standard of care for radiation treatment planning. An additional 18F-FES PET/CT brain scan will be completed before this standard of care radiation treatment. Patients will be followed prospectively with clinical and MRI assessments per standard-of-care for a total of 12 months.
Study Population: Patients with ER-positive breast cancer with biopsy proven or suspected new or recurrent brain metastases (based on standard of care MRI) planned for radiation treatment of brain lesions.
What is being tested
- Brain Imaging with 18F-FES (diagnostic test)
Sponsor: Weill Medical College of Cornell University · Participants: 20 · Started: Dec 27, 2023
Contact the study team
- Jana Ivanidze, MD/PhD · Phone: 212-746-4587
- Alexis Watson · Phone: 646-962-2347
Official record on ClinicalTrials.gov — NCT06072807
Locations in the U.S.
| New York | New York-Presbyterian/Weill Cornell Medical Center, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.